ClinicalTrials.govpublic full text
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
primary central nervous system lymphoma, recurrent cancer, refractory cancer, relapsed cancer, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 911197
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.